Spatially-Resolved Recent Star Formation History in NGC 6946

The nearby face-on star forming spiral galaxy NGC 6946 is known as the Fireworks Galaxy due to its hosting an unusually large number of supernova. We analyze its resolved near-ultraviolet (NUV) stellar photometry measured from images taken with the Hubble Space Telescope's (HST) Wide Field Camera 3 (WFC3) with F275W and F336W filters. We model the color-magnitude diagrams (CMD) of the UV photometry to derive the spatially-resolved star formation history (SFH) of NGC 6946 over the last 25 Myr. From this analysis, we produce maps of the spatial distribution of young stellar populations and measure the total recent star formation rate (SFR) of nearly the entire young stellar disk. We find the global SFR(age$\leq$25 Myr)=$13.17 \substack{+0.91 \\-0.79} M_\odot/\rm yr$. Over this period, the SFR is initially very high ($23.39\substack{+2.43\\-2.11} M_\odot/\rm yr$ between 16-25 Myr ago), then monotonically decreases to a recent SFR of $5.31\substack{+0.19\\-0.17} M_\odot/\rm yr$ in the last 10 Myr. This decrease in global star formation rate over the last 25 Myr is consistent with measurements made with other SFR indicators. We discuss in detail two of the most active regions of the galaxy, which we find are responsible for 3% and 5% of the total star formation over the past 6.3 Myr.Comment: 19 pages, 11 figures, accepted for publication in Ap

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

Considering the Single and Binary Origins of the Type IIP SN 2017eaw

Current population synthesis modeling suggests that 30%–50% of Type II supernovae originate from binary progenitors; however, the identification of a binary progenitor is challenging. One indicator of a binary progenitor is that the surrounding stellar population is too old to contain a massive single star. Measurements of the progenitor mass of SN 2017eaw are starkly divided between observations made temporally close to core collapse, which show a progenitor mass of 13–15 M _⊙ (final helium-core mass {M}_{\mathrm{He},\mathrm{core}}=4.4\mbox{--}6.0\,{M}_{\odot } —which is a more informative property than initial mass) and those from the stellar population surrounding the SN, which find M ≤ 10.8 M _⊙ ( ${M}_{\mathrm{He},\mathrm{core}}\leqslant 3.4\,{M}_{\odot }$ ). In this paper, we reanalyze the surrounding stellar population with improved astrometry and photometry, finding a median age of ${16.8}_{-1.0}^{+3.2}$ Myr for all stars younger than 50 Myr ( ${M}_{\mathrm{He},\mathrm{core}}=4.7{M}_{\odot }$ ) and ${85.9}_{-6.5}^{+3.2}$ Myr for stars younger than 150 Myr. 16.8 Myr is now consistent with the helium-core mass range derived from the temporally near-explosion observations for single stars. Applying the combined constraints to population synthesis models, we determine that the probability of the progenitor of SN 2017eaw being an initially single star is 65% compared to 35% for prior binary interaction. 85.9 Myr is inconsistent with any formation scenarios. We demonstrate that combining progenitor age constraints with helium-core mass estimates from red supergiant SED modeling, late-time spectra, and indirectly from light-curve modeling can help to differentiate single and binary progenitor scenarios and provide a framework for the application of this technique to future observations

Transforming Growth Factor-β Receptor Type 1 (TGFβRI) Kinase Activity but Not p38 Activation Is Required for TGFβRI-Induced Myofibroblast Differentiation and Profibrotic Gene Expression

Transforming growth factor-β (TGFβ) is a major mediator of normal wound healing and of pathological conditions involving fibrosis, such as idiopathic pulmonary fibrosis. TGFβ also stimulates the differentiation of myofibroblasts, a hallmark of fibrotic diseases. In this study, we examined the underlying processes of TGFβRI kinase activity in myofibroblast conversion of human lung fibroblasts using specific inhibitors of TGFβRI (SD-208) and p38 mitogen-activated kinase (SD-282). We demonstrated that SD-208, but not SD-282, inhibited TGFβ-induced SMAD signaling, myofibroblast transformation, and collagen gel contraction. Furthermore, we extended our findings to a rat bleomycin-induced lung fibrosis model, demonstrating a significant decrease in the number of myofibroblasts at fibroblastic foci in animals treated with SD-208 but not those treated with SD-282. SD-208 also reduced collagen deposition in this in vivo model. Microarray analysis of human lung fibroblasts identified molecular fingerprints of these processes and showed that SD-208 had global effects on reversing TGFβ-induced genes involved in fibrosis, inflammation, cell proliferation, cytoskeletal organization, and apoptosis. These studies also revealed that although the p38 pathway may not be needed for appearance or disappearance of the myofibroblast, it can mediate a subset of inflammatory and fibrogenic events of the myofibroblast during the process of tissue repair and fibrosis. Our findings suggest that inhibitors such as SD-208 may be therapeutically useful in human interstitial lung diseases and pulmonary fibrosis

Astrometric Confirmation and Preliminary Orbital Parameters of the Young Exoplanet 51 Eridani b with the Gemini Planet Imager

We present new Gemini Planet Imager observations of the young exoplanet 51 Eridani b that provide further evidence that the companion is physically associated with 51 Eridani. Combining this new astrometric measurement with those reported in the literature, we significantly reduce the posterior probability that 51 Eridani b is an unbound foreground or background T-dwarf in a chance alignment with 51 Eridani to 2 7 10-7, an order of magnitude lower than previously reported. If 51 Eridani b is indeed a bound object, then we have detected orbital motion of the planet between the discovery epoch and the latest epoch. By implementing a computationally efficient Monte Carlo technique, preliminary constraints are placed on the orbital parameters of the system. The current set of astrometric measurements suggest an orbital semimajor axis of AU, corresponding to a period of years (assuming a mass of 1.75 Mo for the central star), and an inclination of deg. The remaining orbital elements are only marginally constrained by the current measurements. These preliminary values suggest an orbit that does not share the same inclination as the orbit of the distant M-dwarf binary, GJ 3305, which is a wide physically bound companion to 51 Eridani.Peer reviewed: YesNRC publication: Ye

The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease.

AIM There is a requirement of an expansive and up to date review of surgical management of inflammatory bowel disease (IBD) that can dovetail with the medical guidelines produced by the British Society of Gastroenterology. METHODS Surgeons who are members of the ACPGBI with a recognised interest in IBD were invited to contribute various sections of the guidelines. They were directed to produce a procedure based document using literature searches that were systematic, comprehensible, transparent and reproducible. Levels of evidence were graded. An editorial board was convened to ensure consistency of style, presentation and quality. Each author was asked to provide a set of recommendations which were evidence based and unambiguous. These recommendations were submitted to the whole guideline group and scored. They were then refined and submitted to a second vote. Only those that achieved >80% consensus at level 5 (strongly agree) or level 4 (agree) after 2 votes were included in the guidelines. RESULTS All aspects of surgical care for IBD have been included along with 157 recommendations for management. CONCLUSION These guidelines provide an up to date and evidence based summary of the current surgical knowledge in the management of IBD and will serve as a useful practical text for clinicians performing this type of surgery